Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

Actiphage shortlisted for Vet Record Innovation Award 2021

Actiphage, the rapid diagnostic for Bovine TB and Johne's Disease, has been short-listed for the Vet Record Innovation Award 2021. The award is for an innovation that has brought about – or has the potential to bring about – a change or improvement in any aspect of veterinary practice.
  • February 11, 2021
  • Award
  • award, Vet Record
Mark Hammond, PBD Biotech CEO

The awards invited nominations for a broad range of innovations – physical, technical, digital or procedural, and is designed to recognise excellence and innovation within the veterinary world.

PBD Biotech CEO, Mark Hammond, will join Sarah Wolfensohn of University of Surrey and Rachel Kirkby of Test&Trace to present their innovations live to a panel of experts at a webinar taking place on 15 February 2021.

Actiphage offers improved management of bTB and Johne’s Disease

Actiphage rapidly and accurately detects and identifies live mycobacteria, the pathogen that causes bovine tuberculosis and Johne’s Disease, in blood or milk samples. Offering the potential of effective disease management for the first time.

Clinical tests are defined by two measures, specificity and sensitivity. The UK Government estimates the accuracy of the Single Intradermal Comparative Cervical Tuberculin (SICCT) skin test to be:

  • Specificity 99.98% – the ability of the test to correctly reject healthy animals that don’t have bovine tuberculosis.
  • Sensitivity 50 -90% – refers to the ability of the test to correctly identify animals that are infected with the disease.
  • Therefore, for a herd with a hundred cows infected with bTB, the SICCT test would miss up to 50; leaving behind a reservoir of infection.

Another issue is that SICCT measures the immune response of the animal, rather than detecting the presence of the mycobacteria and actual infection. Therefore, the skin test may miss cattle that are in the early stages of infection that have not yet developed a strong immune response to the infection and also give a false positive to animals that have been vaccinated.

Actiphage provides direct detection confirming the presence of M. bovis at very early stages of infection, enabling disease management through the removal of these animals from the herd or prior to movement. It also supports the introduction of a vaccine which would provide the ultimate protection of herds.

This webinar is affiliated to the Animal Health Investment Europe Forum, a virtual event 22–23 February 2021.

Share:

Related posts

Loading...
bury_free_press_business_awards_2019

PBD Biotech’s new TB test wins West Suffolk Award for Innovation

October 14, 2019
PBD Biotech has been awarded The West Suffolk Award for Innovation for its rapid accurate blood test, which, by detecting TB in humans and animals at early stage, will help to eradicate this devastating disease.
bury_free_press_business_awards_2019

PBD Biotech’s new TB test wins West Suffolk Award for Innovation

October 14, 2019
PBD Biotech has been awarded The West Suffolk Award for Innovation for its rapid accurate blood test, which, by detecting...
Actiphage mycobacterial diagnostic

Dairy-Tech Royal Innovation Dairy Award announces Actiphage as finalist

January 31, 2019
PBD Biotech is delighted that its novel Actiphage® testing technology has been shortlisted as a finalist for the Royal Dairy Innovation Award, to be presented at this year’s Dairy-Tech (6 February 2019).
Actiphage mycobacterial diagnostic

Dairy-Tech Royal Innovation Dairy Award announces Actiphage as finalist

January 31, 2019
PBD Biotech is delighted that its novel Actiphage® testing technology has been shortlisted as a finalist for the Royal Dairy...

PBD Biotech wins Canadian Innovation Award for Mycobacterial detection technology

August 1, 2017
PBD Biotech Ltd, a Suffolk, UK-based company, has won the top Innovation award for Crop or Livestock technology at the Ag-in-Motion Expo in Saskatoon, Canada.

PBD Biotech wins Canadian Innovation Award for Mycobacterial detection technology

August 1, 2017
PBD Biotech Ltd, a Suffolk, UK-based company, has won the top Innovation award for Crop or Livestock technology at the...

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More